Celtil score and long-term survival outcome in early stage HER2-positive (HER2+) breast cancer treated with anti-HER2-based chemotherapy: A correlative analysis of neoALTTO trial
Nuria Chic1, Stephen Luen2, Paolo Nuciforo3, Roberto Salgado2, Debora Fumagalli4, Florentine Hilbers5, Yingbo Wang6, Evandro de Azambuja7, Itsvan Lang8, Serena Di Cosimo9, Cristina Saura10, Jens Huober11, Aleix Prat1 and Sherene Loi2
Communication in congress
ePoster
SABCS
2020
